H. HAHNE, TECHNISCHE UNIVERSITÄT MÜNCHENTwo teams presented in Nature this week (May 29) the first near-complete drafts of the human proteome.
“While other large proteomic data sets have been collected that cataloged up to 10,000 proteins, the real breakthrough with these two projects is the comprehensive coverage of more than 80 percent of the expected human proteome which has not been achieved previously,” said Hanno Steen from Boston Children's Hospital, who was not involved in the work.
Both teams have published their respective data sets, Human Proteome Map and ProteomicsDB, online.
“The prevalent view was that information transfer was from genome to transcriptome to proteome. What these efforts show is that it’s a two-way road—proteomics can be used to annotate the genome,” added Steen. “The genomics field can now hugely benefit from proteomics data.”
VOLKER THIEL, EDWARD TRYBALAK22, a molecule that interferes with the replication vesicles of coronaviruses (CoVs), has shown promise as a potential treatment for SARS and MERS in an in vitro study published in PLOS Pathogens this week (May 29). And the anti-CoV appeared to work against every virus the team tested, suggesting it could be developed into a treatment for other emerging CoVs that make the jump from animals to people.
